SIGY.OTC.PinkSigyn Therapeutics, INC
10-Q: Sigyn Therapeutics Reports First Quarter 2024 Results, Cites Ongoing Development of Blood Purification Technologies
Sentiment:
Quarterly Report
Sigyn Therapeutics reported its first quarter 2024 results, highlighting ongoing development of its blood purification technologies and a net loss of $758,088.
Capital raiseThe company intends to raise additional funds by way of a public offering or an asset sale transaction.The company has issued convertible notes and warrants to raise capital.The company's ability to continue as a going concern is dependent on its ability to raise additional funds.
Worse than expectedThe company reported a net loss of $758,088 for the first quarter of 2024, which is worse than the net loss of $1,341,036 for the same period in 2023.The company's operating expenses increased by 20.9% year-over-year, indicating higher spending without corresponding revenue.The company has a working capital deficit of $4,100,320, which is a concerning financial position.
Summary
- Sigyn Therapeutics, a development-stage company, reported a net loss of $758,088 for the three months ended March 31, 2024, compared to a net loss of $1,341,036 for the same period in 2023.
- The company's operating expenses increased to $629,972 from $521,258 year-over-year, primarily due to higher research and development costs.
- Sigyn had no revenue for the quarter, consistent with its status as a development-stage company.
- The company's cash balance was $32,838 as of March 31, 2024, up from $11,690 at the end of 2023.
- The company has a working capital deficit of $4,100,320 as of March 31, 2024.
- Sigyn is developing blood purification technologies, including Sigyn Therapy, ChemoPrep, ChemoPure, and ImmunePrep.
- The company is preparing an Investigational Device Exemption (IDE) for submission to the FDA for a human feasibility study of Sigyn Therapy in End-Stage Renal Disease (ESRD) patients.
- The company has issued convertible notes and warrants to raise capital, and some noteholders have converted debt into common and preferred stock.
Sentiment
Score: 4
Explanation: The document presents a mixed picture. While the company is actively developing its technologies and has secured some funding, the significant net loss, working capital deficit, and material weaknesses in internal controls raise concerns. The company's reliance on future capital raises and the lack of revenue also contribute to a negative sentiment.
Positives
- The company's cash balance increased from $11,690 at the end of 2023 to $32,838 as of March 31, 2024.
- The company is actively developing multiple blood purification technologies.
- The company is preparing an IDE for FDA submission for a human feasibility study of Sigyn Therapy.
- The company has made progress in its research and development efforts, including in vitro and in vivo studies.
- The company has secured additional funding through the issuance of convertible notes.
Negatives
- The company reported a net loss of $758,088 for the first quarter of 2024.
- The company has a working capital deficit of $4,100,320 as of March 31, 2024.
- The company has no revenue, consistent with its development-stage status.
- The company's operating expenses increased by 20.9% year-over-year.
- The company has identified material weaknesses in its internal controls over financial reporting.
- The company's ability to continue as a going concern is dependent on its ability to raise additional funds or transact an asset sale.
Risks
- The company has a limited operating history and has not generated any revenue since inception.
- The company's ability to continue as a going concern is dependent on its ability to raise additional capital.
- The company is subject to risks inherent in the establishment of a new business enterprise, including limited capital resources and possible cost overruns.
- The company's success is subject to numerous contingencies, some of which are beyond management's control.
- The company has identified material weaknesses in its internal controls over financial reporting.
- There is no assurance that the company will receive FDA market approval for any of its product candidates.
- The company may not be able to obtain additional financing on commercially reasonable terms, if at all.
Future Outlook
The company intends to raise additional funds by way of a public offering or an asset sale transaction. Management believes that the actions presently being taken to further implement its business plan and generate revenues provide the opportunity for the Company to continue as a going concern. The company plans to initiate first-in-human feasibility studies of Sigyn Therapy in End-Stage Renal Disease (ESRD) patients with endotoxemia and concurrent inflammation. The company is also developing ChemoPrep, ChemoPure, and ImmunePrep for cancer therapy enhancement.
Management Comments
- Management intends to raise additional funds by way of a public offering or an asset sale transaction.
- Management believes that the actions presently being taken to further implement its business plan and generate revenues provide the opportunity for the Company to continue as a going concern.
- Management believes that despite our material weaknesses set forth above, our condensed consolidated financial statements for the three months ended March 31, 2024 are fairly stated, in all material respects, in accordance with U.S. GAAP.
Industry Context
The company is operating in the blood purification technology sector, which is focused on developing treatments for life-threatening conditions such as sepsis, community-acquired pneumonia, and drug-resistant bacterial infections. The company's technologies also target cancer therapy enhancement. The company's focus on broad-spectrum mechanisms aligns with the industry's emerging interest in multi-mechanism therapies.
Comparison to Industry Standards
- The company's lack of revenue is typical for a development-stage company in the biotechnology and medical device sectors.
- The company's focus on blood purification technologies is similar to other companies in the space, such as Terumo BCT, ExThera Medical Corporation, CytoSorbents, Inc., and Baxter Healthcare Corporation, which have received FDA Emergency Use Authorizations for their devices.
- The company's development of multiple product candidates, including Sigyn Therapy, ChemoPrep, ChemoPure, and ImmunePrep, is a common strategy for companies in this sector to diversify their pipeline and mitigate risk.
- The company's reliance on convertible notes and warrants for financing is a common practice for early-stage companies in the biotechnology and medical device sectors.
- The company's reported material weaknesses in internal controls are not uncommon for smaller reporting companies, but require remediation to ensure financial reporting reliability.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Financial Officer | NA | Gerald DeCiccio | 2023-12-06 | New hire |
| Chief Scientific Officer | NA | Annette Marleau | 2023-04-01 | New hire |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board of Directors Appointments | Richa Nand, Jim Dorst, and Christopher Wetzel were appointed as non-executive members to the Board of Directors. | 2022-10-10 | Increased board oversight and expertise. |
Legal Proceedings
- The company is not currently involved in legal proceedings that could reasonably be expected to have a material adverse effect on its business, prospects, financial condition or results of operations.
Related Party Transactions
- The company borrows funds from the CEO for working capital purposes from time to time.
- The company has employment agreements with its CEO, CFO, and CSO.
- The company has a balance due to the CFO for services rendered prior to his employment.
Stakeholder Impact
- Shareholders face the risk of dilution due to the issuance of convertible notes and warrants.
- Employees are impacted by the company's financial performance and ability to continue as a going concern.
- Customers and patients may benefit from the company's development of new blood purification technologies.
- Creditors face the risk of non-payment if the company is unable to raise additional capital.
- Suppliers are impacted by the company's ability to pay for goods and services.
Next Steps
- The company plans to submit an Investigational Device Exemption (IDE) to the FDA for a human feasibility study of Sigyn Therapy.
- The company intends to continue the development of its ChemoPrep, ChemoPure, and ImmunePrep technologies.
- The company plans to raise additional funds through a public offering or asset sale transaction.
- The company plans to implement changes to remediate material weaknesses in internal control over financial reporting.
Key Dates
| Date | Description |
|---|---|
| 2020-01-28 | Date of issuance of a convertible promissory note to Osher Capital Partners LLC. |
| 2020-06-23 | Date of issuance of a convertible promissory note to Osher Capital Partners LLC. |
| 2020-09-17 | Date of issuance of a convertible promissory note to Osher Capital Partners LLC. |
| 2020-10-19 | Date of the Share Exchange Agreement with Sigyn Therapeutics, Inc. |
| 2021-05-27 | Date the company entered into a lease for its corporate office. |
| 2022-03-23 | Date of issuance of a convertible promissory note to Osher Capital Partners LLC and Brio Capital Master Fund Ltd. |
| 2022-04-28 | Date of issuance of a convertible promissory note to Osher Capital Partners LLC. |
| 2022-05-10 | Date of issuance of a convertible promissory note to Brio Capital Master Fund Ltd. |
| 2022-06-01 | Date of issuance of a convertible promissory note to Osher Capital Partners LLC. |
| 2022-06-22 | Date of issuance of a convertible promissory note to Osher Capital Partners LLC. |
| 2022-08-31 | Date of issuance of a convertible promissory note to Osher Capital Partners LLC. |
| 2022-09-09 | Date of issuance of a convertible promissory note to Brio Capital Master Fund Ltd. |
| 2022-09-20 | Date of issuance of a convertible promissory note to Osher Capital Partners LLC. |
| 2022-10-20 | Date of issuance of a convertible promissory note to Osher Capital Partners LLC. |
| 2022-11-09 | Date of issuance of a convertible promissory note to Brio Capital Master Fund Ltd. |
| 2022-11-14 | Date of issuance of a convertible promissory note to Osher Capital Partners LLC. |
| 2022-12-22 | Date of issuance of a convertible promissory note to Osher Capital Partners LLC. |
| 2023-04-01 | Date Dr. Annette Marleau became the company's Chief Scientific Officer. |
| 2023-12-06 | Date Mr. DeCiccio was hired as the company's Chief Financial Officer. |
| 2024-01-08 | Date of issuance of a convertible promissory note to Brio Capital Master Fund Ltd. |
| 2024-01-19 | Date of the one-for-forty reverse stock split. |
| 2024-02-29 | Date of various convertible note transactions with Osher Capital Partners LLC and Brio Capital Master Fund Ltd. |
| 2024-03-31 | End of the reporting period for the quarterly report. |
| 2024-04-09 | Date of various convertible note transactions with Brio Capital Master Fund Ltd. |
| 2024-04-10 | Date of various convertible note transactions with Osher Capital Partners LLC. |
| 2024-05-14 | Date of the report, and the number of shares of common stock outstanding. |
Keywords
blood purification, Sigyn Therapy, endotoxemia, sepsis, cancer therapy, chemotherapy, immunotherapy, medical devices, FDA, clinical trials, convertible notes, warrants, extracorporeal, renal disease
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.